Market Newsdesk

• Zoom Virtual Agent expands to Zoom Phone, enabling a new concierge use case that delivers personalized support with agentic concierge capabilities to automate routine calls and streamline frontline service across departments
• Zoom AI Companion enhances agentic scheduling to coordinate meetings end-to-end, finding the best time, contacting attendees, tracking responses, and recommending next steps without the back-and-forth
• Zoom Hub launches, providing a centralized workspace to create, find, and manage Zoom files
• Zoom Team Chat adds AI Companion to mobile for easier catch-up, and quick document summaries without needing to open the file in the Zoom Workplace desktop app, saving time and boosting productivity

SAN JOSE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced a new concierge use case for Zoom Virtual Agent, now integrated with Zoom Phone, giving businesses a smarter way to answer calls and better support callers from the start. Zoom also announced the launch of Zoom Hub, a centralized content center to help users organize, manage, and create Zoom assets, and enhanced AI features across Zoom Meetings and Team Chat to help teams work faster and stay aligned in real time.

A 24/7 AI receptionist that does more than route calls

Zoom Virtual Agent, now integrated with Zoom Phone, provides an elevated concierge experience that goes beyond basic call answering services or auto-attendants. As your newest front desk team member, the concierge greets callers, speaks naturally, processes input, and initiates the most appropriate next step. From booking appointments to providing updates and routing to the right person without phone trees or long hold times, it helps organizations reduce missed calls and deliver a more professional first impression.

“When someone calls your business, it should feel easy and personal from the first hello. By combining AI that can listen, understand, and take action with the reach of Zoom Phone, our concierge virtual agent provides seamless and personalized support to all callers,” said Smita Hashim, chief product officer at Zoom. “Whether a customer is calling to schedule an appointment, check an order status, or check product availability, Zoom’s concierge is available 24×7 and can deliver answers instantly, escalating to live employees only when needed. The result is a faster, more personalized, and more scalable experience for everyone.”

Admins can save time and avoid tech headaches by easily deploying the concierge within minutes using a no-code configuration. By uploading documents or pointing to a website, teams can quickly train the concierge to greet callers and respond to real-world questions. Built to work with diverse audiences, it supports natural, multilingual conversations in English, Spanish, French, German, Portuguese, and Japanese, with more on the way, and is available 24/7 so callers get a fast, consistent experience any time of the day.

Zoom Virtual Agent (ZVA) concierge supports a wide range of use cases, including:

• Healthcare: In fast-paced care settings, ZVA concierge can help patients get connected with the care they need quickly. It can route calls to the right department, answer common questions like “Are you accepting new patients?”, and let patients book appointments by phone, even after hours, freeing staff to focus on care delivery.
• Retail: When customers call with specific needs like finding the right product for a project or checking if an item is in stock, ZVA concierge can answer their questions, confirm if an item is in stock (even down to the aisle), schedule pickup, and more, all without requiring human assistance.
• Manufacturing: For companies juggling service requests and product support, ZVA concierge can capture customer requests, guide them through troubleshooting over the phone, and direct them to the right team, day or night, without manual intake.
• Financial services: Personalized service is critical in financial conversations. ZVA concierge can greet clients, gather information about why they’re calling, and resolve the request on the spot, like providing application updates, or connect them to the right advisor with all the details already captured, reducing wait times while providing a high-touch experience.

The Zoom Virtual Agent phone concierge capability is available today. To learn more or request a demo, visit zoom.com.

Agentic meeting scheduling without the back and forth

The AI Companion meeting scheduling skill uses agentic AI to eliminate the friction of finding a time that works for everyone, whether scheduling with colleagues or external partners. Instead of juggling calendars, tracking multiple time zones, and managing out-of-office notices, AI Companion instantly analyzes all of these factors to surface the most convenient options.

Once a preferred time is selected, AI Companion takes over the coordination process, reaches out to invitees directly, sends meeting requests, and keeps a real-time pulse on responses, whether via email or Zoom Team Chat. If a proposed time no longer works, it immediately suggests an alternative, ensuring the conversation keeps moving and the meeting is confirmed quickly.

This end-to-end automation prevents scheduling delays and missed opportunities. AI Companion acts as a dedicated meeting coordinator, removing tedious back-and-forth, reducing scheduling errors, and giving teams more time to focus on the discussion itself, not the logistics.

A new asset hub to stay organized and work efficiently

Zoom Hub, now generally available, introduces a streamlined way for users to stay organized and take action across Zoom Workplace. As a central destination within Zoom Workplace, Zoom Hub works with AI Companion to help users create content more efficiently, while also bringing together Zoom meeting recordings, meeting summaries, docs, whiteboards, clips, and more, eliminating the need to jump between tools or hunt for files.

• Stay organized, with the ability to view your Zoom assets in one place and organize assets by folder.
• Catch up and prepare for meetings easily by searching for files by meeting.
• Kickstart drafts with AI Companion in Zoom Hub, including Zoom docs or data tables, whiteboards, and clips.

A chat experience that works smarter with AI

Zoom Team Chat users can now work smarter on the go with AI Companion built right into the Team Chat compose bar and a refreshed mobile experience, making it easier to draft messages and catch up on unread messages. When using Team Chat in the Zoom Workplace desktop app, users can now see a summary of a document by selecting the summarize icon when hovering over the file card without having to open the file, helping save more time.

Additionally, to help improve AI Companion’s ability to handle agentic tasks like meeting scheduling and translating conversations into actionable outcomes for users, Zoom will be among the first to integrate OpenAI’s GPT-5 into its AI stack.

Zoom AI Companion’s new agentic capabilities and enhancements help users save time in the workday and are included at no additional cost with paid Zoom Workplace plans. These updates reinforce Zoom’s commitment to building a truly AI-first collaboration platform that helps teams work faster, stay aligned, and focus on what matters most.

To learn more about Zoom Workplace, visit the Zoom website.

About Zoom

Zoom’s mission is to provide an AI-first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion that empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Zoom Public Relations

Travis Isaman
[email protected]

STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO^® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is the first and only therapy approved in the European Union (EU) to treat desmoid tumors.

“Desmoid tumors can have a profound impact on people’s lives and are difficult to manage due to their invasive nature and high rates of recurrence. Until now, there have been no approved medicines in Europe,” said Bernd Kasper, M.D., Ph.D., Professor, University of Heidelberg, Mannheim Cancer Center, Mannheim, Germany, and principal investigator of the DeFi trial. “OGSIVEO is a highly innovative therapy with efficacy data demonstrating both meaningful antitumor activity and a significant improvement in desmoid tumor symptoms, including a significant reduction in pain which is the most debilitating symptom reported by patients.”

“This approval is a long-awaited advance for desmoid tumor patients, their families and physicians in Europe,” said Lynne Hernandez, Executive Director of the Desmoid Tumor Research Foundation. “It is our hope that patients will benefit from greater awareness of desmoid tumors, faster diagnoses, and better outcomes now that there is an approved treatment.”

Desmoid tumors are rare, locally aggressive tumors that form in the connective tissues of the body.^1,2 Approximately 1,300 to 2,300 new cases of desmoid tumors are diagnosed annually in the EU.^3,4,5 These tumors can cause severe pain, limited function, loss of mobility, disfigurement and fatigue.^1,6-10 They are challenging to manage because of their unpredictable nature and high rate of recurrence, which can significantly impact an individual’s quality of life.^2,7,8,11,12 Desmoid tumor experts and treatment guidelines now recommend medical therapy as first-line intervention instead of surgery for most tumor locations requiring treatment.^13,14

“We would like to extend our gratitude to the patients, families, investigators, and advocacy organizations who helped make this EC approval possible,” said Danny Bar-Zohar, MD, CEO of Healthcare and Executive Board Member at Merck KGaA, Darmstadt, Germany. “OGSIVEO is already established as the standard of care systemic therapy for desmoid tumors in the U.S., and our goal is to bring the same treatment benefits to patients in Europe. Following last month’s EC approval of our therapy for patients with NF1-PN, we are in the unique position of launching two innovative treatments — underscoring our commitment to the rare tumor patient community.”

The EC approval of OGSIVEO is based on results from the Phase 3 DeFi trial, which enrolled 142 adult patients with progressing desmoid tumors and met the primary endpoint of improving progression-free survival (PFS). OGSIVEO demonstrated a statistically significant improvement over placebo with a 71% reduction in the risk of disease progression (hazard ratio (HR) = 0.29 (95% CI: 0.15, 0.55); p< 0.001). OGSIVEO also demonstrated a significant improvement in objective response rate (ORR). The confirmed ORR based on RECIST v1.1 was 41% with OGSIVEO versus 8% with placebo (p<0.001); the complete response rate was 7% in the OGSIVEO arm and 0% in the placebo arm. The median time to first response was 5.6 months with OGSIVEO and 11.1 months with placebo. Additionally, OGSIVEO demonstrated early and sustained improvement in patient-reported outcomes (PROs), including pain (p<0.001), desmoid tumor-specific symptoms (p<0.001), physical/role functioning (p<0.001), and overall health-related quality of life (p≤0.01).¹³

OGSIVEO exhibited a manageable safety and tolerability profile. The most common adverse reactions reported in 88 patients receiving OGSIVEO across all studies (69 patients from DeFi and 19 patients from early phase studies) were diarrhea (85%), rash (65%), ovarian toxicity in women of childbearing potential (60%) nausea (59%), fatigue (50%), hypophosphataemia (50%), headache (40%) and stomatitis (40%).¹³

About the DeFi Trial

DeFi (NCT03785964) was a global, randomized (1:1), multicenter, double-blind, placebo-controlled pivotal Phase 3 trial that evaluated the efficacy, safety and tolerability of nirogacestat in adult patients with progressing desmoid tumors. The double-blind phase of the study randomized 142 patients (nirogacestat, n=70; placebo n=72) to receive 150 mg of nirogacestat or placebo twice daily. Key eligibility criteria included tumor progression by ≥20% as measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) within 12 months prior to screening. The primary endpoint was progression-free survival, as assessed by blinded independent central review, or death by any cause. Secondary and exploratory endpoints included safety and tolerability measures, objective response rate, duration of response, changes in tumor volume assessed by magnetic resonance imaging (MRI), and changes in patient-reported outcomes. DeFi also included an open-label extension phase.

About Desmoid Tumors

Desmoid tumors are rare, locally aggressive tumors of the soft tissues that can be serious, debilitating, and, in rare cases when vital structures are impacted, life-threatening.^1,2

Desmoid tumors are most commonly diagnosed in patients between the ages of 20 and 44 years, with a two-to-three times higher prevalence in females.^3,11 It is estimated that there are 1,300-2,300 new desmoid tumor cases diagnosed per year in the European Union. ^3,4,5

Although desmoid tumors do not metastasize, they can be associated with recurrence rates of up to 77% after surgical resection.^11,12 Desmoid tumor experts and treatment guidelines now recommend systemic therapies as first-line intervention for most tumor locations requiring treatment.^14,15

About OGSIVEO

^®

(nirogacestat)

OGSIVEO^® (nirogacestat) is an oral, selective, small molecule gamma secretase inhibitor approved in the United States and European Union as monotherapy for the treatment of adult patients with progressing desmoid tumors who require systemic treatment.

The FDA and the EMA have granted Orphan Drug designation for OGSIVEO for the treatment of desmoid tumors.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

• Diarrhea: Diarrhea occurred in 84% of patients treated with OGSIVEO. Grade 3 events occurred in 16% of patients. Monitor patients and manage using antidiarrheal medications. Modify dose as recommended.
• Ovarian Toxicity: Female reproductive function and fertility may be impaired in patients treated with OGSIVEO. Impact on fertility may depend on factors like duration of therapy and state of gonadal function at time of treatment. Long-term effects on fertility have not been established. Advise patients on the potential risks for ovarian toxicity before initiating treatment. Monitor patients for changes in menstrual cycle regularity or the development of symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.
• Hepatotoxicity: ALT or AST elevations occurred in 30% and 33% of patients, respectively. Grade 3 ALT or AST elevations (>5 × ULN) occurred in 6% and 2.9% of patients. Monitor liver function tests regularly and modify dose as recommended.
• Non-Melanoma Skin Cancers: New cutaneous squamous cell carcinoma and basal cell carcinoma occurred in 2.9% and 1.4% of patients, respectively. Perform dermatologic evaluations prior to initiation of OGSIVEO and routinely during treatment.
• Electrolyte Abnormalities: Decreased phosphate (65%) and potassium (22%) occurred in OGSIVEO-treated patients. Phosphate <2 mg/dL occurred in 20% of patients. Grade 3 decreased potassium occurred in 1.4% of patients. Monitor phosphate and potassium levels regularly and supplement as necessary. Modify dose as recommended.
• Embryo-Fetal Toxicity: Oral administration of nirogacestat to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity at maternal exposures below human exposure at the recommended dose of 150 mg twice daily. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose.

ADVERSE REACTIONS

• The most common (≥15%) adverse reactions were diarrhea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection, and dyspnea.
• Serious adverse reactions occurring in ≥2% of patients were ovarian toxicity (4%).
• The most common laboratory abnormalities (≥15%) were decreased phosphate, increased urine glucose, increased urine protein, increased AST, increased ALT, and decreased potassium.

DRUG INTERACTIONS

• CYP3A Inhibitors and Inducers: Avoid concomitant use with strong or moderate CYP3A inhibitors (including grapefruit products, Seville oranges, and starfruit) and strong or moderate CYP3A inducers.
• Gastric Acid Reducing Agents: Avoid concomitant use with proton pump inhibitors and H2 blockers. If concomitant use cannot be avoided, OGSIVEO can be staggered with antacids (e.g., administer OGSIVEO 2 hours before or 2 hours after antacid use).
• Consult the full Prescribing Information prior to and during treatment for important drug interactions.

To report suspected adverse reactions, contact SpringWorks Therapeutics at 1-888-400-SWTX (1-888-400-7989) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for OGSIVEO for more information.

About SpringWorks Therapeutics

SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany, is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors. We developed and are commercializing the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN). We are also advancing a portfolio of novel targeted therapy product candidates for patients with additional rare tumors and hematological cancers.

For more information, visit www.springworkstx.com and follow @SpringWorksTx on X, LinkedIn, Facebook, Instagram and YouTube.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Contacts:

Media

[email protected]

References

1. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: News and Perspectives. Pathologica. 2021;113(2):70-84. doi:10.32074/1591-951X-213.
2. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol. 2017;29(4):268-274. doi:10.1097/CCO.0000000000000374.
3. van Broekhoven DLM, Grünhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817-2823. doi:10.1245/s10434-015-4632-y.
4. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96-107. doi:10.1016/j.ejca.2019.11.013.
5. Eurostat. Population structure and ageing. European Commission. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing. Accessed June 12, 2025.
6. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol. 2017;29(4):268-274. doi:10.1097/CCO.0000000000000374.
7. Constantinidou A, Scurr M, Judson I, Litchman C. Clinical presentation of desmoid tumors. In: Litchman C, ed. Desmoid Tumors. Springer; 2012:chap 2. https://www.researchgate.net/publication/226455135_Clinical_Presentation_of_Desmoid_Tumors. Accessed June 12, 2025.
8. Bektas, M, et al. Desmoid tumors: a comprehensive review. Adv Therapeutics. 2023. doi.org/10.1007/s12325-023-02592-0.
9. Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? Support Care Cancer. 2019;27(3):965-980. doi:10.1007/s00520-018-4386-8.
10. Gounder MM, Maddux L, Paty J, Atkinson TM. Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. Cancer. 2020;126(3):531-539. doi:10.1002/cncr.32555.
11. Skubitz KM. Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc. 2017;92(6):947-964. doi:10.1016/j.mayocp.2017.02.012.
12. Easter DW, Halasz NA. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann Surg. 1989;210(6):765-769. doi:10.1097/00000658-198912000-00012.
13. OGSIVEO. EMA. Summary of product characteristics (SmPC). SpringWorks Therapeutics, Inc.
14. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96-107. doi:10.1016/j.ejca.2019.11.013.
15. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Soft Tissue Sarcoma V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed June 12, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LONDON, Aug. 18, 2025 (GLOBE NEWSWIRE) — Diginex Limited (“Diginex”) (NASDAQ: DGNX), a leading provider of Sustainability RegTech solutions, today announced the signing of a definitive agreement for an all-share acquisition of Matter DK ApS (“Matter”), an innovative ESG data company focused on delivering sustainability data and analytics solutions to the investment industry and helping financial institutions understand and communicate the sustainability of investments.  Matter is based in Copenhagen, Denmark, and counts a subsidiary of NASDAQ as its main strategic investor.  The transaction values the equity of Matter at $13 million, which will be paid through the issuance of Diginex ordinary shares valued at $83.77 per ordinary share, which shares are subject to an 18-month lock-up period. In connection with the transaction, senior management of Matter will be granted ordinary shares of Diginex valuted at $2.5 million, also valued at $83.77 per ordinary share, that vest in equal proportions over 12 and 24 months.  The transaction is expected to close later within the next quarter, subject to customary closing conditions.

This strategic acquisition aims to enhance Diginex’s portfolio by integrating Matter’s advanced ESG data analytics, benchmarking, and reporting capabilities. The acquisition will enable Diginex to offer more comprehensive ESG solutions to organizations worldwide, helping them navigate the complexities of sustainability and meet evolving regulatory and stakeholder expectations for ESG reporting.

“We are thrilled to advance this acquisition, marking a significant step toward integrating Matter’s expertise into our ecosystem and further strengthening our position in the ESG data space,” said Miles Pelham, Chairman of Diginex. “This combination aligns perfectly with our mission to empower businesses with cutting-edge AI tools to drive sustainable impact and positions us for accelerated growth in a high-potential sector. We’re also happy to welcome Nasdaq as a strategic partner and shareholder.”

“We are delighted to move forward with Diginex under this definitive agreement, and we look forward to the opportunities ahead,” said Niels Fibæk, CEO of Matter. “Together, we will amplify our impact, delivering unparalleled data-driven insights to help organizations achieve their sustainability goals.”

Diginex was advised on the transaction by Gibson, Dunn & Crutcher LLP, and Lund Elmer Sandager as to matters of Danish law.

About Diginex

Diginex Limited (Nasdaq: DGNX; ISIN KYG286871044), headquartered in London, is a sustainable RegTech business that empowers businesses and governments to streamline ESG, climate, and supply chain data collection and reporting. The Company utilizes blockchain, AI, machine learning and data analysis technology to lead change and increase transparency in corporate regulatory reporting and sustainable finance. Diginex’s products and services solutions enable companies to collect, evaluate and share sustainability data through easy-to-use software. 

The award-winning diginexESG platform supports 19 global frameworks, including GRI (the “Global Reporting Initiative”), SASB (the “Sustainability Accounting Standards Board”), and TCFD (the “Task Force on Climate-related Financial Disclosures”). Clients benefit from end-to-end support, ranging from materiality assessments and data management to stakeholder engagement, report generation and an ESG Ratings Support Service.

For more information, please visit the Company’s website:

https://www.diginex.com/.

About Matter

Matter is a pioneering ESG data company that delivers actionable insights to support organizations in achieving their sustainability objectives. Through advanced analytics and reporting, Matter enables businesses to make informed decisions that drive positive environmental and social outcomes. For more information, visit www.thisismatter.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results disclosed in the Company’s filings with the SEC.

Diginex

Investor Relations
Email: [email protected]

IR Contact – Europe

Anna Höffken
Phone: +49.40.609186.0
Email: [email protected]

IR Contact – US

Jackson Lin
Lambert by LLYC
Phone: +1 (646) 717-4593
Email: [email protected]

IR Contact – Asia

Shelly Cheng
Strategic Financial Relations Ltd.
Phone: +852 2864 4857
Email: [email protected]

SHENZHEN, China, Aug. 18, 2025 (GLOBE NEWSWIRE) — Lianhe Sowell International Group Ltd (Nasdaq: LHSW) (the “Company” or “Lianhe Sowell”), a provider of industrial machine vision products and solutions in China, today announced its financial results for the fiscal year ended March 31, 2025.

Key Financial Performance Highlights of Fiscal Year 2025

• Revenues were approximately $36.54 million in the fiscal year ended March 31, 2025, which remained at the same level of approximately $36.60 million in 2024. Revenue from sales of software increased approximately 177% to approximately $14.57 million, driven by strengthened marketing efforts that resulted in significant customer growth. Revenue from sales of electronic products decreased approximately 30% to approximately $21.97 million, reflecting a strategic move towards product offerings with higher‑margins.
• Gross profit was approximately $9.58 million in 2025, up from approximately $7.96 million in 2024. Gross margin was approximately 26% in 2025, up about 4 percentage points from 2024, which was driven by increased sales of higher‑margin software .
• Net income was approximately $3.18 million in 2025, reflecting an increase of approximately 13% as compared to net income in 2024.

Mr. Yue Zhu, CEO and Director of the Company commented: “Fiscal 2025 was a year of strategic transformation for Lianhe Sowell. We maintained stable overall revenues while deliberately reshaping our business mix toward higher‑margin software solutions, which nearly tripled in sales. This shift, combined with disciplined cost management, expanded our gross margin by four percentage points and drove double‑digit growth in net income.”

“We also accelerated innovation in our industrial robotics line, achieving significant milestones in the commercialization of our new generation automated precision vision spray painting robots, both domestically and internationally. The strong market reception, reflected in major orders and deliveries, reinforces our belief that intelligent, automated solutions will be a major growth driver for years to come.”

“Looking ahead, we plan to remain focused on scaling our software and robotics businesses, deepening R&D investment, and executing on our high‑margin growth strategy. With our strengthened product portfolio, robust order pipeline, and the planned expansion of our manufacturing capacity, we are confident in our ability to deliver sustainable value to our shareholders and customers worldwide.”

Selected Fiscal Year 2025 Financial Results

For Fiscal Years Ended March 31
In USD Millions, except %, differences due to rounding.	2025	2024	Variances
			%
Revenues	36.54	36.60	–
Cost of revenues	26.96	28.64	(6.00)
Gross profit	9.58	7.96	20.26
Gross margin	26.00%	22.00%	4 percentage points
Operating income	3.08	2.98	3.23
Net income	3.18	2.82	12.94

Revenue

Total revenues remained stable, with a slight decrease of approximately $0.06 million, from approximately $36.60 million for the year ended March 31, 2024, to approximately $36.54 million for the year ended March 31, 2025. This was primarily due to a significant increase in software sales, which rose by approximately $9.31 million, or approximately 177%, from approximately $5.27 million in 2024 to approximately $14.57 million in 2025.

However, this gain was partially offset by an approximately $9.36 million, or approximately 30%, decline in revenue from electronic product sales, which fell from approximately $31.33 million in 2024 to approximately $21.97 million in 2025. The drop in electronic product sales resulted from the Company’s strategic shift toward higher-margin offerings and a reduction in lower-margin product lines.

The surge in software sales was driven by enhanced marketing efforts, including increased investment in advertising and promotion, which led to rapid customer growth during the year ended March 31, 2025. Additionally, no revenue was generated from the engineering project in either year due to its suspension.

The following table presents revenues by revenue categories for the years ended March 31, 2025 and 2024, respectively:

In USD Millions, except %, differences due to rounding.		For Fiscal Years Ended March 31,
		2025				2024				Variance
Revenue Category		Amount		% of revenues		Amount		% of revenues		Amount		%
Electronic products		21.97		60.00		31.33		86.00		(9.36)		(30.00)
Software		14. 57		40.00		5.27		14.00		9.31		177.00
Engineering project		—		—		—		—		—		—
Total revenues		36.54		100.00		36.60		100.00		(0.06)		—

Cost of Revenues and Margins

Cost of revenues primarily consists of (i) labor expenses, including salaries, social insurance, and benefits, for employees engaged in operations and product support, and (ii) associated costs of materials and equipment. For the year ended March 31, 2025, cost of revenues was approximately $26.96 million, reflecting a decrease of approximately $1.67 million, or approximately 6%, from approximately $28.64 million in the year ended March 31, 2024. This reduction was mainly attributable to the decline in electronic product sales, as the Company shifted its sales focus toward products with higher gross margins and reduced sales of lower-margin electronic products during the year ended March 31, 2025.

As a result, Lianhe Sowell recorded gross profits of approximately $9.58 million and approximately $7.96 million, with gross margins of approximately 26% and approximately 22% for the years ended March 31, 2025 and 2024, respectively. The overall gross margin increased by approximately 4 percentage points, primarily driven by the growth in software sales, which carry higher margins, during the year ended March 31, 2025 compared to 2024.

Operating Expenses

Selling Expenses

Selling expenses increased by approximately $0.46 million, or approximately 142%, from approximately $0.32 million in 2024 to approximately $0.78 million in 2025, mainly due to higher salary and welfare costs.

Salary and welfare rose by approximately $0.32 million, or approximately 222%, driven by the hiring of additional sales staff to support business promotion in 2025.

General and Administrative Expenses

General and administrative expenses decreased by approximately $0.12 million, or approximately 5%, from approximately $2.37 million in 2024 to approximately $2.25 million in 2025.

The decline was primarily due to a reduction in professional fees of approximately $0.29 million, or approximately 41%, mainly from lower payments to the Company’s independent auditor. Meanwhile, provision for doubtful accounts and rental and property management fees increased by approximately $0.06 million, or approximately 5%, and approximately $0.06 million, or approximately 66%, respectively.

Research and Development Expenses

Research and development expenses were approximately $3.46 million in 2025, up approximately $1.18 million, or approximately 51%, from approximately $2.29 million in 2024.

The increase was mainly due to higher spending on third-party R&D services, which rose by approximately $1.23 million, or approximately 76%.

Net Income

As a result of the foregoing, the Company reported a net income of approximately $3.18 million for the year ended March 31, 2025, compared to a net income of approximately $2.82 million for the year ended March 31, 2024.

Recent Developments

On July 24, 2025, Lianhe Sowell announced the successful export and commissioning of 10 sets of its new generation automated precision vision spray painting robots (the “Spray-Painting Robots”) to South Korean client MM Motors Co., Ltd.

On July 10, 2025, Lianhe Sowell announced the successful delivery of one of its Spray-Painting Robots to Mercedes-Benz Asia’s largest Body & Paint center in Beijing, China.

On June 05, 2025, Lianhe Sowell announced entry into sales agreements with seven equipment sales agents for sales of 500 Spray-Painting Robots with full delivery estimated to be completed by Q1 2026. Total sales amount of the order is approximately RMB200 million.

On May 12, 2025, Lianhe Sowell announced it received a letter of intent (the “LOI”) from Hangzhou Yuhang Economic Development Equity Investment Fund, for a funding of no more than RMB200 million. The Company plans to use the proceeds primarily to support research and development of its Spray-Painting Robots and in the construction of its manufacturing base in Hangzhou, Zhejiang province.

On April 04, 2025, Lianhe Sowell completed an initial public offering on the Nasdaq Capital Market to raise aggregate gross proceeds of $8 million, before deducting underwriting discounts and other offering expenses.

About Lianhe Sowell International Group Ltd

Lianhe Sowell International Group Ltd (Nasdaq: LHSW) provides industrial vision and industrial robotics solutions. With expertise in the field of machine vision and intelligent equipment, the Company specializes in smart transportation, industrial automation, artificial intelligence, and machine vision. Committed to offering comprehensive intelligent solutions to customers worldwide, the Company continuously advances the intelligent transformation of various industries through technological innovation. For more information, please visit: http://www.sowellrobot.com/

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “plan” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risk factors discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Lianhe Sowell International Group Ltd
[email protected]

WFS Investor Relations Inc.
Janice Wang
Email: [email protected]
Phone: +86 13811768599
+1 628 283 9214

LIANHE SOWELL INTERNATIONAL GROUP LTD CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2025 and 2024 (Stated in US Dollars)
		As of March 31,
		2025				2024
ASSETS
Current assets:
Cash and cash equivalents		$	108,745			$	206,187
Accounts receivable, net			19,144,103				13,272,976
Prepayments, deposits and other receivables, net			3,321,253				1,200,827
Amount due from related parties, net			69,514				795,924
Amount due from shareholders,			413,350				—
Total current assets			23,056,965				15,475,914
Non-current assets:
Property and equipment, net			67,083				85,370
Intangible assets, net			42,321				11,566
Operating lease right-of-use asset, net			120,918				368,687
Prepayments			6,035,922				2,188,400
Deferred initial public offering (“IPO”) costs			921,217				708,983
Deferred tax assets			484,704				290,967
Total non-current assets			7,672,165				3,653,973
TOTAL ASSETS		$	30,729,130			$	19,129,887
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term bank loans		$	1,996,775			$	1,661,981
Current portion of long-term bank loan			47,247				—
Short-term other borrowing			55,121				—
Loan from a shareholder			—				185,867
Accounts payable			11,782,429				4,795,154
Accrued expenses and other payables			2,863,896				2,624,910
Income tax payable			631,419				455,675
Contract liabilities			500,246				791,265
Operating lease liability – current			123,645				258,709
Warranty provision			1,311				26,459
Amount due to related parties			19,928				9,276
Amount due to shareholders			628,076				68,954
Total current liabilities			18,650,093				10,878,250
Non-current liabilities:
Operating lease liability – non-current			—				113,394
Non-current portion of long-term bank loan			287,872				289,323
Long-term other borrowing			137,804				—
Total non-current liabilities			425,676				402,717
TOTAL LIABILITIES		$	19,075,769			$	11,280,967
SHAREHOLDERS’ EQUITY
Ordinary shares, par value $0.0001; 500,000,000 shares authorized, 50,000,000 shares issued and outstanding as of March 31, 2025 and 2024, respectively		$	5,000			$	5,000
Subscription receivables			—				(5,000	)
Additional paid-in capital			4,374,056				3,688,178
Statutory reserve			297,656				159,109
Retained earnings			6,994,445				4,008,330
Accumulated other comprehensive loss			(75,549	)			(6,547	)
Equity attributable to the shareholders of the Company			11,595,608				7,849,070
Non-controlling interests			57,753				(150	)
Total shareholders’ equity			11,653,361				7,848,920
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$	30,729,130			$	19,129,887

LIANHE SOWELL INTERNATIONAL GROUP LTD CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME FOR THE YEARS ENDED MARCH 31, 2025, 2024 AND 2023 (Stated in US Dollars)
		For the years ended March 31,
		2025				2024				2023
Revenue from third parties		$	36,539,846			$	36,032,665			$	13,070,586
Revenue from a related party			—				566,002				—
REVENUES		$	36,539,846			$	36,598,667			$	13,070,586
COST OF REVENUES			(26,964,611	)			(28,636,850	)			(9,715,604	)
GROSS PROFIT			9,575,235				7,961,817				3,354,982
OPERATING EXPENSES
Selling expenses			(782,523	)			(322,961	)			(251,422	)
General and administrative expenses			(2,250,827	)			(2,369,855	)			(821,432	)
Research and development expenses			(3,462,715	)			(2,286,141	)			(449,828	)
Total operating expenses			(6,496,065	)			(4,978,957	)			(1,522,682	)
OPERATING INCOME			3,079,170				2,982,860				1,832,300
OTHER INCOME (EXPENSE), NET
Interest income			270				696				347
Interest expense			(101,713	)			(57,941	)			(60,242	)
Other income			166,936				203,461				71,586
Other expense			(47,325	)			(201,629	)			(3,639	)
Disposal gain of a subsidiary			60,622				—				—
Total other income (expense), net			78,790				(55,413	)			8,052
INCOME BEFORE INCOME TAXES			3,157,960				2,927,447				1,840,352
Benefit from (provision for) income taxes			24,605				(109,622	)			(230,297	)
NET INCOME			3,182,565				2,817,825				1,610,055
Less: net income (loss) attributable to non-controlling interests			57,903				(89	)			(55	)
Net income attributable to shareholders of the Company			3,124,662				2,817,914				1,610,110
Other comprehensive loss
Foreign currency translation adjustment			(69,002	)			(187,115	)			(100,009	)
Total comprehensive income			3,113,563				2,630,710				1,510,046
Less: comprehensive income (loss) attributable to non-controlling interests			57,903				(89	)			(55	)
		$	3,055,660			$	2,630,799			$	1,510,101
Earning per share – basic and diluted		$	0.06			$	0.06			$	0.03
Basic and diluted weighted average shares outstanding			50,000,000				50,000,000				50,000,000